OBJECTIVE: Little is known about seizures in natalizumab-associated progressive multifocal leukoencephalopathy (NAT-PML). METHODS: A review of clinical records of 15 NAT-PML patients with multiple sclerosis (MS) treated at a German university hospital. RESULTS: Some 53% (8/15) of our patients developed seizures with often multiple semiologies (seven grand mal, three simple partial motor and two psychomotor seizures). Series of seizures or status epilepticus occurred in seven of these eight. Seizure onset was on average 61 days after onset of NAT-PML and was associated with immune reconstitution inflammatory syndrome (IRIS) in five of eight patients. After having observed severe seizures during NAT-PML in seven of our first nine patients, we started preventive antiepileptic treatment (PAT) with levetiracetam (1000-1750 mg/day). Patient subgroups analyzed for seizures and PAT did not differ in baseline characteristics. Only one of six patients, who received PAT, had a seizure compared with seven of nine patients without PAT (2-tailed Fisher's exact test, p = 0.04). CONCLUSIONS: Although the small sample size and retrospective nature of the study are limitations, we propose to treat NAT-PML patients with PAT early after diagnosis, as seizures seem to be common and severe in NAT-PML.
OBJECTIVE: Little is known about seizures in natalizumab-associated progressive multifocal leukoencephalopathy (NAT-PML). METHODS: A review of clinical records of 15 NAT-PMLpatients with multiple sclerosis (MS) treated at a German university hospital. RESULTS: Some 53% (8/15) of our patients developed seizures with often multiple semiologies (seven grand mal, three simple partial motor and two psychomotor seizures). Series of seizures or status epilepticus occurred in seven of these eight. Seizure onset was on average 61 days after onset of NAT-PML and was associated with immune reconstitution inflammatory syndrome (IRIS) in five of eight patients. After having observed severe seizures during NAT-PML in seven of our first nine patients, we started preventive antiepileptic treatment (PAT) with levetiracetam (1000-1750 mg/day). Patient subgroups analyzed for seizures and PAT did not differ in baseline characteristics. Only one of six patients, who received PAT, had a seizure compared with seven of nine patients without PAT (2-tailed Fisher's exact test, p = 0.04). CONCLUSIONS: Although the small sample size and retrospective nature of the study are limitations, we propose to treat NAT-PMLpatients with PAT early after diagnosis, as seizures seem to be common and severe in NAT-PML.
Authors: Ingo Kleiter; Michael Schröder; Ralf Lürding; Gerhard Schuierer; David B Clifford; Ulrich Bogdahn; Andreas Steinbrecher; Peter Pöschl Journal: Mult Scler Date: 2010-05-07 Impact factor: 6.312
Authors: David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath Journal: Lancet Neurol Date: 2010-04 Impact factor: 44.182
Authors: Sarah Gheuens; Long Ngo; Xiaoen Wang; David C Alsop; Robert E Lenkinski; Igor J Koralnik Journal: Neurology Date: 2012-08-22 Impact factor: 9.910
Authors: Werner Wenning; Aiden Haghikia; Jörg Laubenberger; David B Clifford; Peter F Behrens; Andrew Chan; Ralf Gold Journal: N Engl J Med Date: 2009-09-10 Impact factor: 91.245
Authors: Mai Himedan; Sandra Camelo-Piragua; Elizabeth A Mills; Avneesh Gupta; Rany Aburashed; Yang Mao-Draayer Journal: J Investig Med High Impact Case Rep Date: 2017-09-27